Harvard Medical School is considering easing rules on financial ties between faculty researchers and drug companies.
Harvard's current policy is considered among the toughest in the nation. It forbids researchers from owning more than 20-thousand dollars' worth of stock in companies that finance work in their labs. They also can't take more than ten-thousand dollars in consulting fees or spend more than 20 percent of their time on non-Harvard research.
Supporters of easing the rules say a change could speed the development of scientific findings into lifesaving medications. Opponents say current rules minimize corporate influence on the progress of science. The review comes as drug companies expand in the Boston area.
Two faculty committees are scheduled to make their recommendations on June 26th.